US 9,333,144
Application 13/795,683 · Granted May 10, 2016
Devices and methods for increased blood flow and pain control
Estimated expiration
June 27, 2027
218 days remaining
Earliest effective filing
Oct 4, 2006
+ 20 years
Oct 4, 2026
PTA +266d
Jun 27, 2027
No TD
—
Final
Jun 27, 2027
- Earliest effective filing
- Oct 4, 2006
- + 20 years
- Oct 4, 2026
- PTA +266d
- Jun 27, 2027
- No TD
- —
- Final
- Jun 27, 2027
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- March 12, 2013
- Earliest effective filing
- October 4, 2006
- Issue date
- May 10, 2016
- PTA
- +266 days
- Base expiry (before PTA)
- October 4, 2026
October 4, 2006 + 20 years = October 4, 2026 + 266 PTA days = June 27, 2027
- Continuation-in-part of application 13/426,330, filed Mar 21, 2012, issued as US 8,740,960
- Continuation of application 11/538,718, filed Oct 4, 2006, issued as US 8,147,533
- Continuation of application 11/538,718, filed Oct 4, 2006, issued as US 8,147,533
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 13/795,683 · US 9,333,144
PatentReply compiles the prosecution history behind US 9,333,144: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US9333144Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.